Does Anthem Cover Semaglutide (Wegovy)?

How Anthem Structures Wegovy Coverage

Anthem Blue Cross Blue Shield is not a single insurance product. It operates as a federation of regional Blue Cross Blue Shield licensees, and each employer or individual market plan selects its own formulary and benefit design. This means two people with "Anthem" cards can have completely different coverage for the same drug.

The majority of Anthem commercial plans that include an anti-obesity medication (AOM) benefit list Wegovy on a specialty or non-preferred brand tier. A 2024 analysis by the Obesity Coverage Gap Campaign found that only 47% of large-employer plans explicitly covered at least one FDA-approved AOM, meaning more than half still carried outright exclusions for weight management drugs. Anthem plans mirror this split: some cover Wegovy with prior authorization, while others exclude the entire anti-obesity category.

To determine your specific coverage, check your Summary of Benefits and Coverage (SBC) document or call the number on the back of your Anthem card and ask: "Does my plan cover anti-obesity medications, and is semaglutide 2.4 mg (Wegovy) on the formulary?" The answer will fall into one of three categories: covered with prior auth, covered after step therapy, or excluded.

Prior Authorization Requirements for Wegovy Under Anthem

Nearly every Anthem plan that covers Wegovy requires prior authorization (PA) before the pharmacy will dispense the medication. The PA process confirms that the prescriber has documented specific clinical criteria. Anthem's standard medical policy for injectable anti-obesity agents typically requires the following.

A confirmed BMI of 30 kg/m² or higher, or a BMI of 27 kg/m² or higher with at least one weight-related comorbidity. Acceptable comorbidities include type 2 diabetes, hypertension, dyslipidemia, and obstructive sleep apnea. The 2022 American Association of Clinical Endocrinology (AACE) guidelines recommend pharmacotherapy for patients with a BMI of 27 or above when complications are present, and Anthem's PA criteria generally align with this threshold.

Documentation of a structured weight management program (diet and exercise) for at least 3 to 6 months without achieving 5% or greater body weight loss. Some Anthem plans also require a documented trial of a lower-cost oral agent such as phentermine, topiramate, or orlistat before approving Wegovy. This is known as step therapy.

The prescribing physician must submit the PA request through Anthem's online portal or by fax. Approval or denial typically arrives within 72 hours for standard requests and 24 hours for urgent requests. If approved, the authorization is usually valid for 12 months, after which the prescriber must submit a renewal demonstrating continued medical necessity and weight loss progress.

What Wegovy Costs With and Without Anthem Coverage

The retail price of Wegovy without insurance is approximately $1,349.02 per month for the maintenance dose (2.4 mg weekly injection), according to Novo Nordisk's published list price. With Anthem coverage, out-of-pocket costs vary widely depending on your plan's tier placement and cost-sharing structure.

Patients on preferred formulary tiers may see copays between $25 and $75 per fill. Those on non-preferred specialty tiers often face coinsurance of 20% to 40%, which on a $1,349 drug translates to $270 to $540 per month before hitting any out-of-pocket maximum. Plans with high deductibles require patients to pay the full negotiated rate until the deductible is met.

Novo Nordisk offers a manufacturer savings program for commercially insured patients. Eligible individuals can pay as little as $0 per 28-day supply for up to 13 consecutive monthly fills. The savings card cannot be combined with government insurance (Medicare, Medicaid, Tricare) and requires that Wegovy be covered under your plan. Patients whose Anthem plans exclude Wegovy are not eligible for the savings card.

The STEP 1 trial (N=1,961) demonstrated that semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks compared to 2.4% with placebo, and multiple cost-effectiveness analyses have since argued that covering Wegovy reduces downstream spending on obesity-related conditions such as type 2 diabetes, cardiovascular events, and joint replacements [1].

What to Do If Anthem Denies Your Wegovy Claim

A denial does not end the process. Anthem's denial letters include the specific clinical rationale for the decision, and understanding this rationale is the first step toward a successful appeal.

Common denial reasons include: missing documentation of BMI or comorbidities, failure to complete step therapy with a lower-cost agent, lack of evidence of a supervised diet and exercise program, or an outright plan exclusion for anti-obesity medications. The first three can often be resolved by resubmitting with more complete records. A plan-level exclusion is harder to overturn but not impossible if the prescriber can argue medical necessity under a different benefit category.

File an internal appeal within 180 days of the denial. Include a letter of medical necessity from your prescriber that references the FDA label, the AACE/ACE 2022 obesity treatment algorithm, and any relevant comorbidity data specific to your case. A 2023 analysis published in Obesity found that approximately 41% of internal appeals for GLP-1 receptor agonists prescribed for obesity were overturned when supported by physician documentation of comorbidity burden [2].

If the internal appeal fails, request an external review through your state's insurance department. External reviews are conducted by independent physicians and are binding on the insurer in most states. The external review process typically takes 30 to 45 days.

Dr. Fatima Cody Stanford, an obesity medicine physician at Massachusetts General Hospital, has stated: "The single biggest barrier to GLP-1 therapy is not clinical. It is administrative. Patients who qualify under every guideline are still denied coverage because their plan simply excludes the drug category."

Anthem Medicaid and Medicare Plans: Different Rules Apply

If you have Anthem Medicaid (also called Anthem HealthKeepers or similar state-branded products), coverage for Wegovy depends entirely on your state's Medicaid formulary. As of early 2026, fewer than half of state Medicaid programs cover any FDA-approved anti-obesity medication, and those that do often impose stricter prior authorization criteria than commercial plans.

Medicare Part D plans administered by Anthem historically excluded all anti-obesity medications because the Social Security Act prohibited Medicare from covering drugs used for "anorexia, weight loss, or weight gain." The Treat and Reduce Obesity Act has been reintroduced in Congress multiple times but had not passed as of early 2026. However, if your physician prescribes semaglutide for an FDA-approved indication other than obesity (for example, as Ozempic 1 mg for type 2 diabetes), Medicare Part D does cover it under Anthem Medicare plans.

The SELECT trial (N=17,604) showed that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% compared to placebo in adults with overweight or obesity and established cardiovascular disease [3]. Following this data, the FDA expanded Wegovy's label to include cardiovascular risk reduction. This new indication may open a pathway for Medicare coverage under Anthem Medicare Advantage plans when the prescriber documents established cardiovascular disease, though policy implementation varies by plan.

Alternatives If Your Anthem Plan Excludes Wegovy

Not every workaround costs $1,349 per month. Several options exist for Anthem members whose plans exclude Wegovy.

Ozempic (semaglutide 1 mg) for type 2 diabetes. If you have a concurrent diagnosis of type 2 diabetes, your prescriber can write for Ozempic instead. Most Anthem plans cover Ozempic on a preferred or non-preferred brand tier for type 2 diabetes, and the medication contains the same active ingredient. The maximum Ozempic dose is 2 mg weekly, compared to Wegovy's 2.4 mg maintenance dose. The SUSTAIN 6 trial (N=3,297) confirmed semaglutide's cardiovascular safety profile in patients with type 2 diabetes, and weight loss of 4.5 kg over 104 weeks was observed as a secondary outcome [4].

Tirzepatide (Zepbound). Some Anthem plans that exclude Wegovy cover Zepbound (tirzepatide for chronic weight management) or Mounjaro (tirzepatide for type 2 diabetes). The SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg produced 22.5% mean body weight reduction at 72 weeks compared to 3.1% with placebo [5]. Check your Anthem formulary for tirzepatide before assuming all GLP-1 agents are excluded.

Compounded semaglutide. During FDA-recognized shortages of branded semaglutide, 503A and 503B compounding pharmacies produced semaglutide preparations. The FDA has taken enforcement actions against certain compounders as branded supply stabilized. Patients considering compounded semaglutide should verify current FDA shortage status and only use compounding pharmacies registered with state boards.

Employer benefit advocacy. If your Anthem coverage comes through an employer, request that your HR department add anti-obesity medications to the formulary during the next plan renewal cycle. The American Medical Association, AACE, and the Obesity Medicine Association all classify obesity as a chronic disease requiring pharmacotherapy, and employers increasingly recognize that covering AOMs can reduce total healthcare spending over time.

How the FDA Cardiovascular Label Expansion Affects Anthem Coverage

The FDA's March 2024 supplemental approval of Wegovy for cardiovascular risk reduction changed the coverage calculus for some Anthem plans. Before this approval, Wegovy was indicated solely for chronic weight management. Insurers could classify it as a "lifestyle" drug and exclude it. The cardiovascular indication makes this classification harder to defend.

Anthem plans that cover cardiovascular medications but exclude anti-obesity drugs now face a paradox: the same drug, at the same dose, treats a condition the plan does cover. Some Anthem regional affiliates began updating their medical policies in late 2024 and early 2025 to cover Wegovy when prescribed specifically for cardiovascular risk reduction in patients with established atherosclerotic cardiovascular disease (ASCVD) and a BMI of 27 or above.

The 2023 AHA/ACC guidelines for managing overweight and obesity in patients with cardiovascular disease now recommend GLP-1 receptor agonists as a first-line pharmacotherapy option when lifestyle intervention alone is insufficient [6]. Prescribers can cite this guideline in prior authorization requests to argue that Wegovy is being prescribed for cardiovascular risk reduction, not solely for weight loss.

Dr. Donna Ryan, professor emerita at Pennington Biomedical Research Center, noted in a 2024 commentary: "SELECT changed the reimbursement conversation permanently. You cannot call a drug cosmetic when it has a 20% MACE reduction."

How to Check Your Specific Anthem Formulary

Three methods will confirm whether your Anthem plan covers Wegovy.

First, visit Anthem's online formulary lookup tool. Log into your Anthem member portal, manage to "Find a Drug" or "Pharmacy," and search for "semaglutide" or "Wegovy." The results will show the tier, prior authorization requirements, quantity limits, and any step therapy prerequisites.

Second, call Anthem's pharmacy benefits line. The number is on your member ID card, typically on the back. Ask specifically: "Is Wegovy, NDC 00169-4100-XX, covered under my plan for chronic weight management? What are the prior authorization criteria?" Write down the reference number for the call.

Third, ask your prescriber's office to run a real-time pharmacy benefit check through their electronic prescribing system. This will return your plan-specific coverage status, estimated copay, and any PA requirements before the prescription is even sent to the pharmacy.

If you discover your plan excludes anti-obesity medications entirely, ask Anthem for the specific exclusion language in your certificate of coverage. This document is the legal contract between you and the insurer, and it will clarify whether the exclusion applies to all weight management drugs or only specific agents. Some plans exclude "anorexiants" but not "GLP-1 receptor agonists prescribed for cardiometabolic risk," which may leave a pathway for coverage under the cardiovascular indication.

Timeline for Getting Wegovy Through Anthem

From first appointment to first injection, the process typically takes 2 to 6 weeks when prior authorization is required. Your physician submits the PA request after your initial visit. Anthem responds within 72 hours (standard) or 24 hours (urgent). If approved, the specialty pharmacy ships the medication within 3 to 5 business days. If denied, the appeal process adds 30 to 60 days.

During the dose-escalation phase (weeks 1 through 16), patients use lower-dose pens (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg) before reaching the 2.4 mg maintenance dose. Some Anthem plans require separate PA for each dose tier. Others approve the full escalation schedule under a single authorization. Confirm this with your specialty pharmacy to avoid interruptions between dose steps.

Patients who experience a gap in authorization during escalation may need to restart the titration schedule, which delays reaching the therapeutic dose and may reduce early weight loss outcomes. The Wegovy prescribing information specifies a 16-week escalation schedule, and skipping doses or restarting can increase gastrointestinal side effects [7].